Prometheus founded in 2007, committed to the research, development, production, and sales of in vitro diagnostic reagents. It is the first manufacturer in China to start developing and manufacturing drug abuse products and the first FDA approved manufacturer in Asia. Its products have obtained NMPA registration in China, FDA registration in the United States, and CE registration in Europe. Its leading products are rapid diagnostic products, including five series of drug abuse, women's health, infectious diseases, cardiac markers, and tumor markers.

Prometheus, a Chinese company with headquarters in Hangzhou, is dedicated to developing genuine partnerships with its clients by offering prompt, excellent, and precise diagnostics products and services. Prometheus is currently the preferred vendor for many consumers both domestically and abroad because of its high quality requirements, excellent product design, and one-stop shop services. Prometheus covers a broad range of topics, including those related to drug tests, women's health, cardiac markers, infectious disease, and tumor markers. The Prometheus factory has received certification for ISO 9001:2008 and IS013485:2003. The US FDA investigated Prometheus' manufacturing facility in November 2012, but no 483 form was produced. The company currently enjoys a solid sales record for its goods in the United States, Europe, Australia, New Zealand, Chile, Brazil, and other nations, earning it the title of "reliable product supplier" on the international market.